Stephens Inc Veracyte, Inc. Transaction History

Stephens Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$20.96 - $26.99 $3,416 - $4,399	163 Added 0.44%	37,577 $957,000
Q1 2023 May 15, 2023	SELL	$20.58 - $27.89 $16,628 - $22,535	-808 Reduced 2.11%	37,414 $834,000
Q4 2022 Jan 25, 2023	SELL	$15.31 - $29.94 $523,984 - $1.02 Million	-34,225 Reduced 47.24%	38,222 $907,000
Q3 2022 Nov 02, 2022	SELL	$16.58 - $27.9 $24,223 - $40,761	-1,461 Reduced 1.98%	72,447 $1.2 Million
Q2 2022 Aug 03, 2022	BUY	$15.45 - $29.52 $905,848 - $1.73 Million	58,631 Added 383.79%	73,908 $1.47 Million
Q1 2022 May 04, 2022	BUY	$21.94 - $42.51 $335,177 - $649,425	15,277 New	15,277 $421,000
Q3 2019 Oct 18, 2019	SELL	$23.87 - $30.93 $445,414 - $577,153	-18,660 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$22.1 - $28.56 $412,386 - $532,929	18,660 New	18,660 $532,000

311

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.9B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

Stay updated on Stephens Inc with notifications on news.